Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.

Trial Details

NCT ID
NCT06959082
Phase
PHASE2
Sponsor
VSPharmTech Co.,Ltd.
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • VS-101
  • Cisplatin
  • Radiation
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Manhattan, New York, United States|40.78343,-73.96625

Key Eligibility Criteria

  • Males or females aged more than 18 years at the time of ICF signing
  • Diagnosed based on position emission tomography (PET), computed tomography (CT), or magnetic resonance imaging (MRI) with pathologically confirmed …
  • Defined by American Joint Committee on Cancer \[AJCC\] Guidelines 8th Edition:
  • Oral cavity, hypopharynx, or larynx (independent of p16): Stage III, IVa, IVb per TNM guidelines; or

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →